-
公开(公告)号：US20240325593A1
公开(公告)日：2024-10-03
申请号：US18400466
申请日：2023-12-29
IPC分类号： A61L24/06 , A61B8/08 , A61B17/12 , A61B17/34 , A61B17/42 , A61F6/22 , A61K49/22 , A61L24/00 , A61L27/52 , A61L27/54
CPC分类号： A61L24/06 , A61B8/0833 , A61B8/0841 , A61B8/085 , A61B17/12 , A61B17/12022 , A61B17/12186 , A61B17/3403 , A61F6/22 , A61K49/223 , A61K49/226 , A61L24/001 , A61L24/0015 , A61L24/0031 , A61L24/0036 , A61L27/52 , A61L27/54 , A61B8/0891 , A61B8/481 , A61B8/488 , A61B2017/3413 , A61B17/42 , A61L2300/626 , A61L2400/06 , A61L2430/36
摘要： Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
公开(公告)号：US20180326088A1
公开(公告)日：2018-11-15
申请号：US16042789
申请日：2018-07-23
发明人： John C. Herr , Eusebio S. Piers , Austin Herr
IPC分类号： A61K47/68 , C07K16/28 , C07K16/30 , G01N33/574
CPC分类号： A61K47/6813 , A61K47/6825 , A61K47/6849 , A61K47/6851 , C07K16/28 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/732 , C07K2317/74 , C07K2317/77 , C07K2319/55 , C12Y302/02022 , G01N33/57492
摘要： The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.
-
3.发明申请公开(公告)号：US20160195538A1
公开(公告)日：2016-07-07
申请号：US14980984
申请日：2015-12-28
发明人： John C. Herr , Eusebio S. Pires
IPC分类号： G01N33/574 , C12Q1/68 , C07K16/40
CPC分类号： G01N33/57492 , A61K38/1709 , A61K39/3955 , C07K16/40 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/574 , G01N33/57442 , G01N33/57449 , G01N33/6884 , G01N33/689 , G01N33/6893 , G01N2333/705
摘要： The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.
摘要翻译： 基于以下发现，本发明提供了用于诊断，治疗和预防癌症，特别是卵巢癌和子宫癌的组合物和方法，即发现作为精子蛋白受体的卵母细胞特异性蛋白质SAS1R（Sperm Acrosomal SLLP1 Receptor）是精子蛋白受体 也在各种癌症中表达，包括卵巢癌和子宫癌。 以前已经确定了六种SAS1R变体，并且它们被本发明所包含。 本发明进一步提供可用于靶向表达SAS1R细胞并用于杀死此类细胞的抗体。
-
公开(公告)号：US20150125445A1
公开(公告)日：2015-05-07
申请号：US14407399
申请日：2013-06-13
申请人： University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group
发明人： John C. Herr , Eusebio S. Pires , Austin Herr
IPC分类号： A61K47/48 , G01N33/574
CPC分类号： A61K47/6813 , A61K47/6825 , A61K47/6849 , A61K47/6851 , C07K16/28 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/732 , C07K2317/74 , C07K2317/77 , C07K2319/55 , C12Y302/02022 , G01N33/57492
摘要： The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.
摘要翻译： 本发明提供使用免疫毒素技术靶向SAS1B阳性癌细胞的组合物，并且公开了肾和胰腺癌细胞是SAS1B阳性但不是正常的肾脏和胰腺细胞。 本发明公开了尽管仅在正常组织中雌性生长的卵母细胞中表达，SAS1B在男性和女性的癌症中表达。
-
公开(公告)号：US20190060513A1
公开(公告)日：2019-02-28
申请号：US16173539
申请日：2018-10-29
IPC分类号： A61L24/06 , A61F6/22 , A61B8/08 , A61B17/12 , A61B17/34 , A61L27/54 , A61L27/52 , A61L24/00 , A61K49/22 , A61B17/42
摘要： Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
公开(公告)号：US10155063B2
公开(公告)日：2018-12-18
申请号：US15349824
申请日：2016-11-11
IPC分类号： A61F6/20 , A61L24/06 , A61B17/34 , A61F6/22 , A61K49/22 , A61L24/00 , A61B8/08 , A61L27/52 , A61L27/54 , A61B17/12
摘要： Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
公开(公告)号：US20170298141A1
公开(公告)日：2017-10-19
申请号：US15581214
申请日：2017-04-28
发明人： John C. Herr , Eusebio S. Pires , Austin Herr
IPC分类号： C07K16/30 , G01N33/574 , C07K16/28
CPC分类号： A61K47/6813 , A61K47/6825 , A61K47/6849 , A61K47/6851 , C07K16/28 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/732 , C07K2317/74 , C07K2317/77 , C07K2319/55 , C12Y302/02022 , G01N33/57492
摘要： The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.
-
公开(公告)号：US11904068B2
公开(公告)日：2024-02-20
申请号：US17651509
申请日：2022-02-17
IPC分类号： A61B17/34 , A61F6/22 , A61L24/00 , A61L24/06 , A61L27/52 , A61L27/54 , A61K49/22 , A61B8/08 , A61B17/12 , A61B17/42
CPC分类号： A61L24/06 , A61B8/085 , A61B8/0833 , A61B8/0841 , A61B17/12 , A61B17/12022 , A61B17/12186 , A61B17/3403 , A61F6/22 , A61K49/223 , A61K49/226 , A61L24/001 , A61L24/0015 , A61L24/0031 , A61L24/0036 , A61L27/52 , A61L27/54 , A61B8/0891 , A61B8/481 , A61B8/488 , A61B17/42 , A61B2017/3413 , A61L2300/626 , A61L2400/06 , A61L2430/36
摘要： Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
公开(公告)号：US11278641B2
公开(公告)日：2022-03-22
申请号：US16173539
申请日：2018-10-29
IPC分类号： A61F6/22 , A61L24/06 , A61L27/52 , A61L27/54 , A61K49/22 , A61B8/08 , A61B17/12 , A61B17/34 , A61L24/00 , A61B17/42
摘要： Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
-
公开(公告)号：US20180066052A1
公开(公告)日：2018-03-08
申请号：US15670640
申请日：2017-08-07
发明人： John C. Herr , Monika Sachdev , Arabinda Mandal
CPC分类号： C07K16/28 , A61K38/1709 , A61K38/177 , A61K38/4886 , A61K39/0006 , C07K2317/76 , G01N2333/96486 , G01N2500/04
摘要： The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females. Together, the results suggest SAS1R is a proteolytically active, oocyte and early embryo specific oolemmal metalloprotease receptor for the sperm intra-acrosomal ligand SLLP1 and is a target for regulating fertilization and as a contraceptive.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.031 秒)
